Astellas Pharma, Medivation announce topline results from enzalutamide Phase 2 STRIVE

[News]

Astellas Pharma Inc. and Medivation, Inc. today announced topline results from the Phase 2 STRIVE trial comparing enzalutamide with bicalutamide in a study population of men with non-metastatic or metastatic castration-resistant prostate cancer.

More... (http://www.news-medical.net/news/20150402/Astellas-Pharma-Medivation-announce-topline-results-from-enzalutamide-Phase-2-STRIVE-trial.aspx)